A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs GTL 001 (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GENTICEL
- 01 Dec 2016 Status changed from recruiting to discontinued.
- 29 Oct 2015 Results from this trial are expected during the first half of 2016, according to a Genticel media release.
- 29 Oct 2015 Status changed from not yet recruiting to recruiting, according to a Genticel media release.